Analysis of Johnson & Johnson Vaccine Effectiveness for Preventing COVID-19

By JAMA Network November 2, 2021

At 11:00 a.m. ET today (November 2, 2021), the results will be released for research that analyzed the effectiveness of the Johnson & Johnson vaccine for preventing COVID-19. The study will be published in JAMA Network Open, a monthly open access medical journal published by the American Medical Association.

What the study did: The findings of this study, involving 8,889 patients who received a single dose of the Ad26.COV2.S (Johnson & Johnson) COVID-19 vaccine and 88,898 unvaccinated patients, are consistent with the efficacy of Ad26 reported in clinical trials. COV2. S, suggesting that the vaccine is effective in reducing SARS-CoV-2 infection, even with the spread of variants such as Alpha or Delta that were not present in the original studies, and reaffirms the urgent need for mass vaccination. -continue efforts worldwide.

Authors: Tyler Wagner, Ph.D., and Venky Soundararajan, Ph.D., of nference in Cambridge, Massachusetts, are the corresponding authors.

Link: JAMA Network Open

Reference: November 2, 2021, JAMA Network Open.
DOI: 10.1001 / jamanetworkopen.2021.32540